James T. Handa, M.D., is Chief of the Retina Division and the Robert Bond Welch, M.D., Professor of Ophthalmology at the Wilmer Eye Institute. He specializes in medical and surgical management of complex vitreoretinal diseases such as age-related macular degeneration, diabetic retinopathy, retinal detachment, retinopathy of prematurity and other pediatric retinal diseases. He also has expertise in intraocular oncology and manages patients with choroidal melanomas and metastatic tumors of the eye. Not only is he a highly skilled surgeon and clinician, but he also devotes significant effort to research related to the early causes of age-related macular degeneration using molecular pathological approaches to understand how the eye transforms from normal aging to early disease. He has been funded by the National Eye Institute for the last 19 years, and he currently holds two R01 awards for his work in AMD. He has also been funded by the Thome Foundation, Research to Prevent Blindness, Fight for Sight and the American Health Assistance Foundation. His other research focuses on surgical innovation using an integrated robotic surgical system. Dr. Handa is currently the Wilmer Eye Institute’s implanting surgeon for the Argus II retinal chip implant, which was recently approved by the FDA after Dr. Handa participated in the clinical trial leading to its approval. Dr. Handa is rated as a Distinguished provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Melanoma of the Eye, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Metastatic Uveal Melanoma, and Vitrectomy.

Mary Aronow is an Ophthalmologist in Mount Airy, Maryland. Dr. Aronow is rated as a Distinguished provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Melanoma of the Eye, Choroid Plexus Carcinoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Vitrectomy. Dr. Aronow is currently accepting new patients.

Akrit Sodhi, M.D, Ph.D., is an Associate Professor of Ophthalmology at the Wilmer Eye Institute and holds the Branna and Irving Sisenwein Professorship in Ophthalmology. Dr. Sodhi specializes in the medical and surgical management of complex vitreoretinal diseases. Dr. Sodhi was trained at the University of California at Los Angeles (UCLA), the University of California at Davis, and the National Institutes of Health. After obtaining his M.D. and Ph.D., he interned at Sinai Hospital in Baltimore and completed his Ophthalmology Residency training at the Wilmer Eye Institute at Johns Hopkins in 2008. He then pursued a fellowship in vitreoretinal surgery at Wilmer where he also served as the Assistant Chief of Service (Chief Resident). Dr. Sodhi joined the faculty of the Retina Division at Wilmer in 2010. His research interests, currently sponsored by grants from the National Eye Institute, include the examination of the role of hypoxia inducible factor (HIF) and HIF-regulated genes in ocular diseases, including diabetic eye disease, age-related macular degeneration, sickle cell retinopathy, retinal vein occlusions, and uveal melanoma. Dr. Sodhi's lab has identified novel therapeutic targets for the treatment of these vision-threatening diseases. Dr. Sodhi is rated as an Advanced provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Late-Onset Retinal Degeneration.

Marc Ernstoff is an Oncologist in Frederick, Maryland. Dr. Ernstoff is rated as an Experienced provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, and Urothelial Cancer.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Experienced provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Sahaja Acharya is the Director of Pediatric Radiation Oncology within the Department of Radiation Oncology and Molecular Radiation Sciences. She specializes in pediatric brain tumors, pediatric sarcomas, and adult sarcomas. She is also the Associate Director for the Radiation Oncology Residency Program. She leads the Pediatric Radiation Oncology program at the Johns Hopkins Hospital and treats patients at both Johns Hopkins Hospital and Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, pediatric malignancies, and adult sarcoma. She is the Principal Investigator on external grants from ASCO Conquer Cancer, the Department of Defense, and the Carson Leslie Foundation. She is also the Principal Investigator of phase II pediatric brain tumor clinical trials. She has been invited to participate in multiple national and international guideline committees and regularly lectures on pediatric malignancies and proton therapy. Dr. Acharya received her Bachelor's in Chemistry and Political Science from Stanford University and her medical degree from Saint Louis University. She completed radiation oncology residency at Washington University in St. Louis. Dr. Acharya is rated as an Experienced provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Brain Tumor, Gliomatosis Cerebri, Glioma, and Posterior Fossa Tumor.

Fatemeh Rajaii, M.D., Ph.D., is an associate professor of ophthalmology at the Wilmer Eye Institute, Johns Hopkins Medicine. Dr. Rajaii specializes in reconstructive and cosmetic eyelid, orbital and facial surgery. This includes the surgical treatment of eyelid malpositions, facial skin cancers, tear drainage issues, orbital tumors and Thyroid Eye Disease. She treats children and adults. Dr. Rajaii's research interests include the effects of eyelid surgery on ocular surface disease and visual function, oculoplastic surgical techniques and mechanisms underlying orbital disease. Dr. Rajaii received her M.D. and Ph.D. (neuroscience) degrees from Johns Hopkins University School of Medicine. She completed an internship in internal medicine at Mercy Medical Center prior to completing her ophthalmology residency at the Wilmer Eye Institute. She completed a fellowship in ophthalmic plastic, orbital and facial cosmetic surgery at the University of Michigan prior to joining the Wilmer faculty. Dr. Rajaii is rated as an Experienced provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Orbital Cellulitis, Eyelid Drooping, Ptosis, and Periorbital Cellulitis.

Heba Mahjoub is an Ophthalmologist in Baltimore, Maryland. Dr. Mahjoub is rated as an Experienced provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Subconjunctival Hemorrhage, Endophthalmitis, Glaucoma, and Ocular Hypertension (OHT).

Vishal Jindal is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Jindal is rated as an Experienced provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Atheroembolic Renal Disease, Thrombocytopenia, Splenic Infarction, and Anemia. Dr. Jindal is currently accepting new patients.